Prognostic role of maspin expression in melanoma: probably far from clinical use

Ribero, Simone; Senetta, Rebecca; Osella‐Abate, Simona; Scalzo, Maria Stella; Castellano, Isabella; Lentini, Federica; Baboi, Angela Pamela; Fierro, Maria Teresa; Sapino, Anna; Cassoni, Paola

doi:10.1111/his.13188

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been increasing attention to other protease inhibitors, including serpinB1 and maspin (serpinB5), serine protease inhibitor superfamily members. Maspin loss in melanoma could contribute to the metastatic spread and disease progression; however, this remains unclear [86,87].…”

Section: Inhibitors Of Endogenous Enzymesmentioning

confidence: 99%

Role of Biomarkers in the Integrated Management of Melanoma

Naik¹

2021

Disease Markers

View full text Add to dashboard Cite

Melanoma, which is an aggressive skin cancer, is currently the fifth and seventh most common cancer in men and women, respectively. The American Cancer Society reported that approximately 106,110 new cases of melanoma were diagnosed in the United States in 2021, with 7,180 people dying from the disease. This information could facilitate the early detection of possible metastatic lesions and the development of novel therapeutic techniques for melanoma. Additionally, early detection of malignant melanoma remains an objective of melanoma research. Recently, melanoma treatment has substantially improved, given the availability of targeted treatments and immunotherapy. These developments have highlighted the significance of identifying biomarkers for prognosis and predicting therapy response. Biomarkers included tissue protein expression, circulating DNA detection, and genetic alterations in cancer cells. Improved diagnostic and prognostic biomarkers are becoming increasingly relevant in melanoma treatment, with the development of newer and more targeted treatments. Here, the author discusses the aspects of biomarkers in the real-time management of patients with melanoma.

show abstract

Section: Inhibitors Of Endogenous Enzymesmentioning

confidence: 99%

Role of Biomarkers in the Integrated Management of Melanoma

Naik¹

2021

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Some attention also has been paid to other protease inhibitors, namely, maspin (serpinB5) and serpinB1, which both are members of the serine protease inhibitor superfamily. Loss of melanoma maspin has been suggested to contribute to disease progression and metastatic dissemination, but this subject is of controversial debate (41,42). SerpinB1 has been suggested as an indicator of chemotherapy response.…”

Section: Endogenous Enzyme Inhibitorsmentioning

confidence: 99%

Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective

Belter

Haase-Kohn

Pietzsch

2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:The worldwide incidence of malignant melanoma is steadily increasing, suggesting a probable melanoma "epidemic." From a clinical point of view, malignant melanoma still is an unpredictable disease and, once in the advanced stage, allows only scarce therapeutic options. There is an urgent need to identify, characterize, and validate informative biomarkers, biomarker patterns, or surrogate markers in order to not only improve early diagnosis of melanoma but also for differential diagnosis, staging, prognosis, therapy selection, and therapy monitoring. In this chapter, an update on the ongoing debate on serologic and histologic markers such as lactate dehydrogenase, tyrosinase, S100 family of calcium-binding proteins, cyclooxygenase-2, matrix metalloproteinases, and stem and/or progenitor cell markers are presented, and novel, innovative, and promising trends currently being explored are discussed.

show abstract

Prognostic role of maspin expression in melanoma: probably far from clinical use

Cited by 2 publications

References 6 publications

Role of Biomarkers in the Integrated Management of Melanoma

Role of Biomarkers in the Integrated Management of Melanoma

Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective

Contact Info

Product

Resources

About